Storys zum Thema Gesundheit / Medizin
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Isotopia Issues a call to action to the radionuclide Therapy industry.
Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes therapeutic and diagnostic radioactive isotopes. "If you are in the Lu-177 field, don't miss this information." The Lu-177 radiopharmaceuticals sector stands at a critical juncture, necessitating urgent collaboration. Our shared ...
mehrSignia Introduces Hearing Aids That Tackle the Most Difficult Challenge for People With Hearing Loss: Group Conversations in Noise
Lynge, Denmark (ots/PRNewswire) - Hearing aid innovator Signia, part of WS Audiology, today launches Integrated Xperience, a breakthrough technology that enables hearing aid wearers to hear all speakers in noisy group conversations clearly. Even when speakers move or the wearer turns their head, the hearing aids ...
mehrJohnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress
London (ots/PRNewswire) - Next-generation laser vision correction provides next-day results and recovery1,2 - The next-generation ELITATM Femtosecond Laser to correct myopia with the new SILK procedure** - The latest innovation in extended depth of focus (EDOF) intraocular lenses (IOLs) will be shared with invited ...
mehrGerman Bionic Debuts Groundbreaking Power Suit for Nursing and Care Professionals in North America
mehrHuma collaborates with Google Cloud to improve healthcare through generative AI
New York (ots/PRNewswire) - - Huma aims to further support patients and the healthcare workforce by enhancing its regulated Software as Medical Device (SaMD) platform with the addition of generative AI applications - Huma is leveraging Google Cloud's Vertex AI platform and exploring the use of other Google GenAI tools such as Med-PaLM 2 - Huma and Google Cloud are ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrAurisco Pharmaceutical Co.,Ltd.
Successful FDA inspection at Aurisco's manufacturing site in Yangzhou, China
Yangzhou, China (ots/PRNewswire) - Aurisco Pharmaceutical today announced that its cGMP manufacturing plant in Yangzhou has successfully passed a USFDA inspection. Aurisco Pharmaceutical announced today that its API and FDF plant in Yangzhou, China has successfully passed a cGMP inspection by the US Food and Drug Administration (USFDA). The inspection, carried out by ...
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehrCartiHeal Announces First Commercial Implantation of Agili-C™ in the US
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal Ltd., developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of Agili-C in the US by Dr. Ken Zaslav, a specialist in Orthopedic Surgery and Sports Medicine at Northwell Health in New York City, NY. The ...
mehrPRODUCTLIFE GROUP ACQUIRES RNI, EXPANDING ITS SCIENTIFIC AND REGULATORY OFFERING TO SELFCARE PRODUCTS
Paris (ots/PRNewswire) - ProductLife Group, a global provider of regulatory and compliance services for the life sciences industry, strengthens its regulatory expertise in borderline products with the acquisition of RNI, a consulting firm providing global regulatory and scientific services across the entire spectrum ...
mehrPatientGPT from Semalytix Will Replace Six Months of Evidence & Insight Generation in Life Science with Seconds
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrEmpowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
mehrD&A Pharma : Despite the latest alarming figures on alcohol dependence, France is delaying the use of sodium oxybate, which has been prescribed for almost 30 years in Italy and Austria
Paris (ots/PRNewswire) - At the beginning of June, the health authorities hammered it home once again: "The health, social and economic consequences of alcohol consumption represent a burden for French society." The results are alarming: every year in France, alcohol is the cause of 49,000 deaths and an estimated ...
mehrREVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL
Barcelona, Spain (ots/PRNewswire) - - HER2DX® pCR-score was significantly associated with pathological complete response in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab, with or without chemotherapy. - HER2DX® risk-score identified 85% of patients with an invasive disease event as ...
mehrCroma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China
Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...
mehrHuma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform
New York and London (ots/PRNewswire) - - Class II clearance expands the patient population that can be managed - Companies working with Huma's platform can now launch algorithm innovations more quickly in a compliant and de-risked manner, democratising digital health innovation across the industry - Clearance was ...
mehrMenarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma
Istanbul (ots/PRNewswire) - - Data demonstrate a significant 71% reduction in risk of disease progression or death in selinexor + bortezomib + dexamethasone (SVd) arm versus bortezomib + dexamethasone (Vd) arm in PI-naïve patients - Data demonstrate a significant 47% reduction in risk of death with SVd versus Vd in ...
mehrCroma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...
mehrThe Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrHuma named for its successful and innovative approach to clinical trials in new UK government review
New York and London (ots/PRNewswire) - - Huma's innovative approach to medical research cited in Lord James O'Shaughnessy's review for clinical trials improvement in the UK - The review is part of a new widespread policy approach to ignite the UK's life sciences sector - Innovating clinical trials using digital technologies such as Huma's platforms can make them more ...
mehrDeep Breath Intelligence Teams with HTEC Group and Effectum Medical to Accelerate the Launch of CE-marked device under IVDD
Belgrade, Serbia (ots/PRNewswire) - Deep Breath Intelligence (DBI), a MedTech company unleashing the huge potential of exhaled breath analysis through machine learning, has selected HTEC Group and Effectum Medical as primary innovation facilitators to help them achieve greater speed in meeting both software and ...
mehrGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
mehrEuropean study highlights need to improve the quality of conversations about induction of labour (IoL) in clinical settings
Amsterdam (ots/PRNewswire) - - Almost 1 in 2 women (49%) felt the experience of IoL differed from their expectations - The majority of expectant mothers (65%) did not feel fully involved in choosing which method of IoL they prefer - Findings emphasize the importance of collaborative decision-making between ...
mehrDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehr/C O R R E C T I O N -- Croma-Pharma/
Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...
mehrCroma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter
Vienna (ots/PRNewswire) - - Company reports strong financial results for 2022 with 27% revenue growth in 2022 and significantly increased margins - Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as well as strong market growth - Continued market share gains, strategic mid-term ...
mehrNeuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Barcelona, Spain, Düsseldorf, Germany and Paris (ots/PRNewswire) - Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group ("Neuraxpharm"), the leading European specialty pharmaceutical company focused on ...
mehr